Disease Modification in Dermatology: A Novel, First in Class Targeted Therapy for the Non-Immunosuppressive Treatment of Pemphigus & Stevens-Johnson/Toxic Epidermal Necrolysis syndrome
Time: 1:00 pm
day: Day One
Details:
- Development of a human monoclonal antibody against Fas ligand (PC111) that plays a major role in the pathogenesis of pemphigus and Stevens-Johnson/Toxic Epidermal Necrolysis syndrome
- Sharing recent data demonstrating targeted therapy, that acts downstream of the immune system, highly differentiates from currently used potent immunosuppressors, with a good safety profile, meeting patients’ satisfaction
- PC111 will be the first targeted therapy for Stevens-Johnson/Toxic Epidermal Necrolysis syndrome, acute and deadly diseases for which no approved drug exists
